Influx Healthtech targets 2.5-fold capacity increase after IPO proceeds

In H1 FY27, Influx Healthtech said it expects installed manufacturing capacity to increase 2.5 times after using initial public offering (IPO) proceeds, following additions that lifted nutraceutical capacity from 17,000 kilograms per day in FY26 to 22,000 kilograms per day. Its disclosed plan assigns Rs 29 crore to a nutraceutical facility.

How much capacity has Influx Healthtech added before using IPO proceeds?

Influx Healthtech added 6,300 kilograms per day across its three reported operating categories before IPO-proceeds deployment, increasing combined capacity from 21,950 kilograms per day in FY26 to 28,250 kilograms per day in H1 FY27. The presentation describes this pre-IPO expansion as a 25% to 30% increase, while the reported segment figures equate to a 28.7% increase.

Influx Healthtech’s largest absolute addition was in nutraceuticals, where capacity rose by 5,000 kilograms per day. That compared with 1,000 kilograms per day in cosmetics and ayurvedic products and 300 kilograms per day in pet supplements and homecare, making nutraceuticals responsible for most of the reported 6,300-kilogram-per-day increase.

Influx Healthtech reported different utilisation levels across the three segments in H1 FY27. Nutraceutical utilisation was 85%, compared with 65% for pet supplements and homecare and 60% for cosmetics and ayurvedic products, providing the operating context for the company’s proposed next phase of expansion.

Where will Influx Healthtech deploy IPO proceeds?

Influx Healthtech has disclosed Rs 37 crore of capacity-related IPO allocations, led by Rs 29 crore for a new nutraceutical manufacturing facility on a 3,204-square-metre site. A further Rs 6 crore is assigned to a veterinary food manufacturing facility on a 1,350-square-metre site, while Rs 2 crore is planned for machinery in the homecare and cosmetics divisions.

Influx Healthtech expects overall capacity to rise 2.5 times after IPO proceeds are used, based on a strategic reallocation of IPO funds. The presentation does not disclose a post-project installed-capacity figure by segment, so the 2.5-times measure is management’s stated overall expectation rather than a total that can be calculated from the project disclosures.

The planned allocation is distinct from the capacity additions recorded in H1 FY27 because the earlier 6,300-kilogram-per-day increase occurred before IPO-proceeds utilisation. The Rs 29 crore nutraceutical project is nearly five times the Rs 6 crore veterinary-food allocation, while the Rs 2 crore machinery programme is directed to homecare and cosmetics rather than a new manufacturing site.

What production equipment has Influx Healthtech commercialized?

Influx Healthtech commercialized three additions in H1 FY27 through internal accruals and IPO funds: a multi-line production system, an auto tablet coater and a liquid-fill capsule line. The multi-line system adds 250 kilograms per day of tablet production, 35,000 liquid bottles per shift and 50,000 sachets per shift, at an approximate investment of Rs 80 lakh.

The auto tablet coater provides 450 kilograms per day of coating capacity and involved an approximate Rs 40 lakh investment. The liquid-fill capsule manufacturing line can produce 60,000 capsules an hour and involved an approximate Rs 1.5 crore investment. As these assets use kilograms per day, bottles per shift, sachets per shift and capsules per hour, the presentation does not provide one directly comparable output total.

Influx Healthtech’s programme also includes an automated beverage manufacturing line funded through IPO proceeds that was in testing. The line is designed for 10,000 bottles an hour and supports carbonated and non-carbonated beverage formats, distinguishing it from additions described as commercialized in H1 FY27.

How do the planned lines broaden Influx Healthtech’s production formats?

Influx Healthtech’s disclosed machinery spans beverage, single-dose sachet, ready-to-drink nutrition, pet food and blister-packaging formats. Its retort manufacturing system is intended to enable protein shakes and multiple ready-to-drink formats, while the sachet card machine is described as an advanced single-dose packaging technology tailored for Indian market needs.

The high-capacity pet food production line has throughput of 1,000 kilograms an hour and is expected by Influx Healthtech to enhance pet food production capacity about eight times. That multiple applies to the pet food line, whereas the company’s 2.5-times expectation applies to overall capacity after IPO-proceeds utilisation, making the two measures different in scope.

Influx Healthtech also received a four-track aluminium blister packaging machine that is expected to increase blistering capacity by 30%. The company says the equipment improves productivity and reduces packaging cycle time, while the multi-line system’s 50,000-sachet-per-shift output adds further packaging capacity alongside bulk manufacturing additions.

What should readers measure against Influx Healthtech’s capacity target?

Influx Healthtech’s expansion case combines additions already visible in H1 FY27 with facilities and machinery intended to be funded by IPO proceeds. The disclosed starting point is 28,250 kilograms per day of combined capacity across three reported segments, while management’s forward expectation is a 2.5-times increase after proceeds are used.

The key operating comparison will be whether additional capacity is accompanied by utilisation beyond the H1 FY27 levels of 85% in nutraceuticals, 65% in pet supplements and homecare, and 60% in cosmetics and ayurvedic products. The presentation identifies project sites, production lines and machinery but does not disclose future segment-wise utilisation targets or a post-project capacity split.

The company’s 8-person in-house formulation and development team provides another mechanism relevant to expanded output. Influx Healthtech says the unit supports formulation, process and analytical development and has worked across more than 2,345 products, linking product development work with commercial-scale production.

Conclusion

Influx Healthtech has already increased reported capacity by 6,300 kilograms per day from FY26 to H1 FY27, with nutraceuticals contributing 5,000 kilograms per day of that addition. Its next phase carries Rs 37 crore of disclosed IPO allocations across a nutraceutical site, a veterinary-food site and machinery for homecare and cosmetics, alongside new production and packaging assets.

The next items to watch are progress of the automated beverage line beyond testing, deployment of the 1,000-kilogram-per-hour pet food line and the realisation of management’s stated 2.5-times capacity expectation after IPO-proceeds utilisation. H1 FY27 utilisation, especially the 85% reported for nutraceuticals, will indicate how the company is absorbing its expanded manufacturing base.